Systemic treatment of HER2+ metastatic breast cancer: Clinical conundrums and future perspectives

Richard De Boer*, Jane Beith, Jacquie Chirgwin, Sue Chua, Maree Colosimo, Prudence Francis, Michael Green, Ken Pittman, Michelle White, Nicholas Wilcken, Nicholas Zdenkowski, Richard Bell

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Improvements in the treatment of metastatic HER2-positive breast cancer constitute one of the great advances in breast cancer medicine of the last generation. From being a highly aggressive fatal condition, the use of anti-HER2-targeted therapies, in particular trastuzumab, has led to significant improvements in disease outcomes. There are reports of increasing numbers of patients alive and well more than 5 years from diagnosis of metastatic disease. Nevertheless, there remain many complex and clinically difficult scenarios where there is little in the way of randomized evidence or published guidelines to guide decision making. As a companion piece to our review of HER2-targeted therapies in the metastatic setting, we decided to focus on a series of clinical scenarios that fell outside of the standard trial-based settings and where opinions and guidance from experienced clinicians and experts in the field would be considered useful to help develop safe and effective treatment strategies. The following eight cases were put forward by our panel of experts, voted on by their peers to select the most relevant and interesting cases, and the discussions worked on by teams of two followed by review and commentary by another team of two.

Original languageEnglish
Pages (from-to)15-25
Number of pages11
JournalAsia-Pacific Journal of Clinical Oncology
Issue numberS4
StatePublished - Jun 2014
Externally publishedYes


  • Anti-HER2 agent
  • Breast cancer
  • Expert opinion
  • HER2
  • Metastatic


Dive into the research topics of 'Systemic treatment of HER2+ metastatic breast cancer: Clinical conundrums and future perspectives'. Together they form a unique fingerprint.

Cite this